Entellus Medical: Entellus Medical (ENTL) Announces Clinical Study Publication Confirming Nasal Obstruction Symptom Improvement from LATERA

Entellus Medical, Inc., (Nasdaq: ENTL) now a part of Stryker, today announced the publication of positive data from prospective, multicenter OR and Office studies of LATERA for patients with symptoms of Nasal Valve Collapse (NVC) due to lateral wall insufficiency (LWI). Results show that patients treated with LATERA had statistically significant improvements in symptom burden at 1,3, and 6 months post-procedure, as measured by validated scales, including NOSE Scores. For these first 101 patients, symptom reduction of LATERA alone and LATERA plus additional procedures to correct septal deviation and/or turbinate hypertrophy is within the range of other nasal obstruction techniques, including traditional grafting techniques1. The data appear in the latest issue of Laryngoscope.